Document:

EX-10.27

 Exhibit 10.27 

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THIS NOTE MAY NOT BE SOLD, OFFERED FOR
SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS NOTE UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT
REQUIRED. 
 This instrument and the rights and obligations evidenced hereby and any security interests or other liens securing such obligations are
subordinate in the manner and to the extent set forth in that certain Subordination and Intercreditor Agreement dated as of August 19, 2014 (as amended, restated, superseded, replaced, succeeded, substituted, supplemented or otherwise modified
from time to time in accordance with its terms, the “Subordination Agreement”) among Mevion Medical Systems, Inc. (“Borrower”), Life Sciences Alternative Funding LLC (the “Senior Lender”), and the other parties thereto
to all obligations owing by Borrower to Senior Lender (including interest, expenses and fees) as described in the Subordination Agreement. Each holder of this instrument, by its acceptance hereof, irrevocably agrees to be bound by the provisions of
the Subordination Agreement. 
 MEVION MEDICAL SYSTEMS, INC. 

 
  

PROMISSORY NOTE 
  

			
	$[            ]	  	August 19, 2014

 FOR VALUE RECEIVED, Mevion Medical Systems, Inc., a Delaware corporation (the “Company”),
hereby promises to pay to the order of CHL Medical Partners III Side Fund, L.P. (the “Investor”) the principal amount of
[                    ]. Notwithstanding any other provision of this Note, the holder hereof does not intend to charge and the Company shall
not be required to pay any interest. 
 This Note is one of a series of Notes issued by the Company pursuant to and entitled to the benefits
of a certain Note and Warrant Purchase Agreement, dated as of the date hereof, among the Company and the persons listed on Schedule I thereto (as the same may be amended or otherwise modified from time to time, hereinafter referred to as
the “Purchase Agreement”), and the holder of this Note, by its acceptance hereof, agrees to be bound by the provisions of the Purchase Agreement, including the amendment and waiver provisions set forth therein. This Note will be
registered on the books of the Company or its agent as to principal. Any transfer of 

 
this Note will be effected only by surrender of this Note to the Company and reissuance of a new note to the transferee in accordance with the terms herein. Capitalized terms used, but not
otherwise defined herein, shall have the meanings ascribed to such terms in the Purchase Agreement. 
  

	 	1.	Required Vote Repayment. At any time on or after August     , 2015 (the “Maturity Date”), upon the earlier of (i) the written election of the holders of Notes
representing the Required Vote and (ii) upon the occurrence of an Event of Default pursuant to the terms of Section 9 of the Purchase Agreement (subject to any cure periods), this Note shall immediately be repaid. 

 

	 	2.	Payment Mechanics and Prepayment. All payments shall be made in lawful money of the United States of America at such place as the Investor hereof may from time to time designate in writing to the Company. The
Notes shall not be prepaid without the prior written consent of the holders of the Notes representing the Required Vote, and if prepayment is approved, a proportional pari passu payment must be made with respect to all of the Notes then outstanding.

  

	 	3.	Transfer and Exchange. The Investor may, prior to maturity thereof, surrender such Note at the principal office of the Company for transfer or exchange. This Note may be transferred only upon its surrender to the
Company for registration of transfer, duly endorsed, accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Principal shall be paid solely to the registered holder of this Note. Such payment shall
constitute full discharge of the Company’s obligation to pay such principal. Within a reasonable time after notice to the Company from such holder of its intention to make such transfer or exchange and without expense to such holder, except for
any transfer or similar tax which may be imposed on the transfer or exchange, the Company shall issue in exchange therefor another note or notes (each, a “Transferee Note”) for the same aggregate principal amount as the unpaid
principal amount of the Note so surrendered, having the same maturity, containing the same provisions and subject to the same terms and conditions as the Note so surrendered. Each Transferee Note shall be made payable to such person or persons, or
transferees, as the holder of such surrendered Note may designate, and such transfer or exchange shall be made in such a manner that no gain or loss of principal shall result therefrom. Principal shall be paid solely to the registered holder of this
Note. The Company may elect not to permit a transfer of the Note if it has not obtained satisfactory assurance that such transfer: (a) is exempt from the registration requirements of, or covered by an effective registration statement under, the
Securities Act of 1933, as amended, and the rules and regulations thereunder, and (b) is in compliance with all applicable state securities laws, including without limitation receipt of an opinion of counsel for the Investor (or other holder,
as the case may be), which opinion shall be reasonably satisfactory to the Company. 

  

	 	4.	New Note. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Note, the Company will issue a new Note, of like tenor and amount, in lieu of such
lost, stolen, destroyed or mutilated Note, and in such event the Investor (or other holder, as the case may be) agrees to indemnify and hold harmless the Company in respect of any such lost, stolen, destroyed or mutilated Note. 

	 	5.	Expenses of Collection. The Company agrees, subject only to limitations imposed by applicable law, to pay the holder’s reasonable costs in collecting and enforcing this Note, including reasonable
attorney’s fees. 

  

	 	6.	Right or Remedy. A right or remedy under this Note on any occasion shall not be a bar to exercise of the same right or remedy on any subsequent occasion or of any other right or remedy at any time.

  

	 	7.	Notice. Any notice required or permitted under this Note shall be in writing (including email or telecopy communications) and shall be deemed to have been given on the date of delivery, if personally delivered to
the party to whom notice is to be given, or on the fifth business day after mailing, if mailed to the party to whom notice is to be given, by certified mail, return receipt requested, postage prepaid or when delivered via confirmed email or
telecopy, and addressed as follows: 

 if to the Company, at 

Mevion Medical Systems, Inc. 

Attn: Chief Executive Officer 

300 Foster Street 

Littleton, MA 01460 

Fax: (978) 540-1501 

Email: joe@mevion.com 

with a copy (which shall not constitute notice) to: 

Mitchell S. Bloom, Esq. 

Goodwin Procter LLP 

Exchange Place 

53 State Street 

Boston, MA 02109 

Fax: 617-523-1231 

if to the holder, at the most recent address provided to the Company by the holder for such purpose; or, in each case, to the most recent
address, specified by written notice, given to the sender pursuant to this paragraph. 
  

	 	8.	Successors and Assigns. This Note applies to, inures to the benefit of, and binds the successors and assigns of the parties hereto. 

 

	 	9.	Governing Law. This Note shall be governed by and construed in accordance with the internal laws of the State of Delaware. 

  

	 	10.	 Severability. In the event any one or more of the provisions of this Note shall for any reason be held to be invalid, illegal or unenforceable,
in whole or in part or in any 

	 	
respect, or in the event that any one or more of the provisions of this Note operate or would prospectively operate to invalidate this Note, then and in any such event, such provision(s) only
shall be deemed null and void and shall not affect any other provision of this Note and the remaining provisions of this Note shall remain operative and in full force and effect and in no way shall be affected, prejudiced, or disturbed thereby.

 [Remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the undersigned has caused this instrument to be executed by its duly
authorized officer as of the date first above written. 
  

			
	MEVION MEDICAL SYSTEMS, INC.
		
	By:	 	 
	Name:	 	Joseph Jachinowski
	Title:	 	Chief Executive Officer

  
 [Note – CHL
Medical Partners III Side Fund, L.P.]EX-10.28

 Exhibit 10.28 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY
WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

AMENDMENT NO. 1 TO LOAN AGREEMENT 

This Amendment No. 1 dated as of February 7, 2014 (this “Amendment”) to the Loan Agreement dated as of
June 25, 2013 (the “Existing Loan Agreement”) is entered into between Life Sciences Alternative Funding LLC, a Delaware limited liability company, as lender (“Lender”), Mevion Medical Systems,
Inc., a Delaware corporation, as borrower (“Borrower”), and Mevion Medical Systems UK, LLC, a Delaware limited liability company, as guarantor (“Guarantor”), pursuant to and in accordance with
Section 13.05 of the Existing Loan Agreement. Capitalized terms used herein that are not otherwise defined shall have the meanings ascribed to them in the Existing Loan Agreement. 

The Parties hereby agree as follows: 

ARTICLE I 

AMENDMENT 

Section 1.01. Addition of Definitions. Section 1.01 of the Existing Loan Agreement is hereby amended to add the following
defined terms: 
 “ “Allocated Contract Cost” means (a) $[***], with respect to any U.S.
Included Product Agreement, and (b) $[***], with respect to any Non-U.S. Included Product Agreement. 

“Non-U.S. Included Product Agreement” means any Included Product Agreement pursuant to which Borrower agrees
to sell and deliver Included Product(s) to a Person not located in the United States. 
 “Gross Contract
Value” means, with respect to any Included Product Agreement, the total gross amount received or receivable by Borrower during the term of such Included Product Agreement pursuant such Included Product Agreement, including milestone
payments (defined under the applicable Included Product Agreement as “Price” or otherwise), amounts received or receivable from royalties, minimum royalty payments, profit payments or distributions, and license fees. 

“Included Product Agreement” means any Included License Agreement and any other Contract pursuant to which
Borrower and/or any of its Subsidiaries agrees to sell, directly or indirectly, Included Product(s) to Third Parties that are end-users, out-licensors, distributors or other Third Parties. 

“Margin” means, with respect to each Included Product Agreement, the Gross Contract Value less the Allocated
Contract Cost. 
 “Margin Requirement” means, at any time of determination on or after the Tranche B Funding
Date, the aggregate Margin for all Terminated Included Product Agreements at such time is equal to or less than the Margin Threshold in effect at such time. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 “Margin Threshold” means, as of any time of determination on
or after the Tranche B Funding Date, [***]. 
 “New Included Product Agreement” means any Included Product
Agreement entered into by Borrower on or after the Tranche B Funding Date. 
 “Terminated Included Product
Agreement” means any Included Product Agreement that is terminated in its entirety by any party thereto at any time on or after the Tranche B Funding Date. 

“Termination Payments” means, with respect to any Included Product Agreement, (a) all payments paid or
payable to a party to such Included Product Agreement (other than Borrower or any of its Subsidiaries) in respect of the termination, amendment or replacement of such Included Product Agreement, including any refunds, settlement payments, judgment
payments and securities, and any collections, recoveries, payments, supplements or other compensation, any other remuneration of any kind paid, and any other amounts (including damages, awards, interest and penalties) of any kind or nature paid or
payable by Borrower or any of its Subsidiaries (other than to Borrower or any of its Subsidiaries) in substitution or compensation for, or otherwise in respect of, such termination, plus all reasonable and documented out-of-pocket costs and expenses
(including documented attorneys’ fees) actually incurred by Borrower or any of its Subsidiaries in connection with such termination at any time on or after the Tranche B Funding Date, and (b) the amount of any other reduction in Gross
Contract Value in respect of such Included Product Agreement, including (without duplication) pursuant to a termination in part by any party thereto at any time on or after the Tranche B Funding Date. 

“U.S. Included Product Agreement” means any Included Product Agreement pursuant to which Borrower agrees to
sell and deliver Included Product(s) solely to Persons located in the United States.” 

  
 -2- 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 Section 1.02. Material Adverse Effect. The definition of “Material Adverse
Effect” set forth in Section 1.01 of the Existing Loan Agreement is hereby amended [***] 
 Section 1.03. Notice of Margin
Requirement Compliance. Section 9.03(c) of the Existing Loan Agreement is hereby amended to add the following as a new subsection (iv): 

“(iv) The Margin Requirement shall have been satisfied as of the date of the certificate and at all times during the
period covered by the financial statements delivered to Lender (and, for the avoidance of doubt, only at such times that are on and after the Tranche B Funding Date).” 

Section 1.04. Compliance with Laws and Contracts. Section 9.07(a) of the Existing Loan Agreement is hereby amended to add the
following at the end thereof: 
 “; provided that this Section 9.07(a) shall not prohibit Borrower from
terminating any Included Product Agreement so long as before and after giving effect thereto, the Margin Requirement shall be satisfied” 

Section 1.05. Additional Covenants of Borrower. Section 9.11 of the Existing Loan Agreement is hereby amended to add the
following at the end thereof: 
 “; provided that this Section 9.11 shall not prohibit Borrower from
terminating any Included Product Agreement so long as before and after giving effect thereto, the Margin Requirement shall be satisfied” 

Section 1.06. Activities of Borrower. Section 10.01 of the Existing Loan Agreement is hereby amended to add the following at
the end thereof: 
 “; provided that this Section 10.01 shall not prohibit Borrower from terminating any
Included Product Agreement so long as before and after giving effect thereto, the Margin Requirement shall be satisfied” 

Section 1.07. Transactions with Affiliates. Section 10.06 of the Existing Loan Agreement is hereby deleted and amended and
restated in its entirety as follows: 
 “Section 10.06. Limitation on Transactions with Affiliates. 

Borrower shall not, and shall cause its Subsidiaries not to, directly or indirectly, enter into any transaction or series of related
transactions or participate in any arrangement (including any Transfer or purchase or the rendering of any service) with, or for the benefit of, any Affiliate that is not a Borrower Party (and, in the case of a Borrower Party that is a Subsidiary,
that is not a Subsidiary Guarantor who has complied with the terms hereof, including the execution and delivery of the applicable Security Documents), other than (a) the Loan Documents, (b) Permitted Intercompany Transfers, (c)(i) in
the ordinary course of business of Borrower and (ii) upon fair and reasonable terms no less favorable to Borrower than it would obtain in a 

  
 -3- 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 
comparable arm’s-length transaction with a non-Affiliate, and (d) sales of equity securities by Borrower to existing investors of Borrower in bona fide financing transactions which do
not result in the occurrence of a Change of Control and are otherwise permitted under this Agreement.” 
 Section 1.08. Other
Indebtedness and Agreements; Preferred Stock. Section 10.12(b) of the Existing Loan Agreement is hereby amended to add the following at the end thereof: 

“; provided further that this Section 10.12(b) shall not prohibit Borrower from terminating any Included
Product Agreement so long as before and after giving effect thereto, the Margin Requirement shall be satisfied” 
 Section 1.09.
Event of Default. Section 11.01 of the Existing Loan Agreement is hereby amended to add the following as a new subsection (s): 

“(s) Borrower fails at any time after the Tranche B Funding Date to satisfy the Margin Requirement.” 

ARTICLE II 

ADDITIONAL REPRESENTATION AND WARRANTY 

Borrower, with respect to itself and each of its Subsidiaries, as applicable, hereby represents and warrants to Lender that, except as set
forth on Schedule A attached hereto, neither Borrower nor any of its Subsidiaries has received any written notice or, to the Knowledge of Borrower, oral communication, (i) of the intention or threat of any party to any Included Product
Agreement (other than Borrower or any of its Subsidiaries) to terminate such Included Product Agreement in whole or in part or (ii) requesting any amendment, alteration or modification of such Included Product Agreement or any license,
sublicense or assignment thereunder that (A) has not either been withdrawn in writing or reflected in such Included Product Agreement, or (B) if implemented would reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect. 

  
 -4- 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 ARTICLE III 

MISCELLANEOUS 

Section 3.01. Effect of Amendment. Except as specifically amended by this Amendment, the Existing Loan Agreement shall remain in
full force and effect. All references in the Existing Loan Agreement to “this Agreement” or “herein” shall mean the Existing Loan Agreement as amended by this Amendment. 

Section 3.02. Governing Law. This Amendment shall be governed by and construed in accordance with the Laws of the State of New
York (without giving effect to any conflict of laws principles that would require application of the Laws of another jurisdiction). 

Section 3.03. Counterparts; Facsimile Signatures. This Amendment may be executed and delivered by facsimile signature (including
PDF) and in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 

[The remainder of this page is intentionally left blank.] 

  
 -5- 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 The undersigned executed this Amendment as of the date first set forth above. 

 

			
	Life Sciences Alternative Funding LLC,
	as Lender
		
	By:	 	/s/ Stephen J. DeNelsky
	Name:	 	Stephen J. DeNelsky
	Title:	 	President
	
	Mevion Medical Systems, Inc.,
	as Borrower
		
	By:	 	/s/ Joseph Jachinowski
	Name:	 	Joseph Jachinowski
	Title:	 	President and CEO
	
	Mevion Medical Systems UK, LLC,
	as Guarantor
		
	By:	 	/s/ Joseph Jachinowski
	Name:	 	Joseph Jachinowski
	Title:	 	President and CEO

  
 -6- 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

  

 [***] 

  
 -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]